ArticleRadiology case reports2026
Giant retroperitoneal mass in a young male.
Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retroperitoneal fibromatosis, also referred to as retroperitoneal desmoid-type fibromatosis, is an extremely rare, benign but locally aggressive mesenchymal neoplasm originating from the musculoaponeurotic system. Owing to their indolent growth and nonspecific presentation, these tumors are often asymptomatic at an early stage. When symptoms do occur, they usually result from mass effect on the adjacent structures. We report a 19-year-old male who presented with progressive abdominal distension for 2 years along with a massive abdominal lump occupying all quadrants of the abdomen. Imaging revealed a huge retroperitoneal mass with internal calcification and necrotic components. Core biopsy was consistent with fibromatosis. The patient underwent successful surgical excision of a 12 kg tumor. Postoperative recovery was uneventful, and follow-up at 6 months revealed no recurrence. Since the incidence is rare, maintaining a high index of clinical suspicion along with the use of imaging techniques, such as ultrasonography and CT/MRI scans, is essential for diagnosis. However, histopathology followed by immunohistochemistry is regarded as the gold standard for definitive diagnosis. The primary treatment approach is complete surgical removal with negative margins. Adjuvant therapies may be contemplated in instances of recurrence or when the tumor is unresectable. Early recognition and multidisciplinary management are crucial to optimize outcomes in patients with retroperitoneal fibromatosis. Due to the high recurrence rate, long term follow-up is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.